Inovio Pharmaceuticals Inc logo

Inovio Pharmaceuticals Inc(INO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.43
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INO

11/13/2026: INO (1-star) is currently NOT-A-BUY. Pass it for now.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company that develops DNA medicines and proprietary delivery devices targeting cancers and infectious diseases. Its main operational strength lies in its innovative CELLECTRA delivery platform and late-stage candidates such as INO-3107. The primary investment story centers around potential regulatory approvals and commercial expansion in underserved rare disease indications. However, key risks include a lack of consistent product revenue, ongoing cash burn, high clinical trial uncertainties, and intense competition from larger genetic medicine developers. The stock suits speculative or growth-oriented investors willing to tolerate high volatility while monitoring clinical trial readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential through its innovative DNA medicine pipeline, though lack of commercialized scale introduces execution risk.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp, news-driven price spikes around clinical data readouts and regulatory updates.
Value investorWeak fitLack of consistent earnings and product revenue prevents traditional value-based investment screening.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund clinical trials.
Low-risk investorWeak fitHigh clinical volatility and regulatory uncertainty create significant risk for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage news flow frequently triggers sharp share price fluctuations.
Valuation riskHighValuations are driven by speculative future milestones rather than current cash flows.
Competition risk (biopharmaceutical and genetic medicine competition)Medium / highWell-funded competitors are developing alternative mRNA and viral vector platforms.
Business qualityMediumWhile the technology platform is innovative, the lack of commercial products limits financial resilience.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies heavily on navigating complex clinical trials and regulatory approval processes.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 267.85M USD
Price to earnings Ratio -
1Y Target Price 6.33
Price to earnings Ratio -
1Y Target Price 6.33
Volume (30-day avg) 19.3M shares
Beta 1.73
52 Weeks Range 0.56 - 2.72
Updated Date 11/15/2026
52 Weeks Range 0.56 - 2.72
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -23.71%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INO receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
INO has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+20.8%) is partially offset by weak cash generation (FCF margin -136074.5%), negative revenue growth (-70.0%), weak profitability (net margin -130000.0%).

Financial Health Rating

★★★★★
INO's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 23.5%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is INO's strongest growth driver at +20.8% FY2025 versus FY2024 (solid, 4 stars). By comparison, free-cash-flow growth (+15.0%, solid) is also solid, while revenue growth (-70.0%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 33.8% (moderate) and 99.8% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.32%, which materially reduces the ownership score.

Top 5 Institutional Investors

FMR Inc 7.67%
Jupiter Topco LLC 4.69%
Vanguard Capital Management, LLC 3.31%
Boxer Capital Management, LLC 2.58%
ADAR1 Capital Management LLC 1.95%

Unit Economics (Per $1K Revenue)

★★★★★
INO generates approximately $1,000 of gross profit, $-1,328,713 of operating income, and $-1,360,745 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
INO has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Grants and CollaborationsFunding from government agencies, non-profit organizations, and collaborative research agreements.Revenue is sporadic and depends on partnership milestones rather than commercial product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 16.58
Enterprise Value 226.77M
Price to Sales(TTM) 896.11
Enterprise Value 226.77M
Price to Sales(TTM) 896.11
Enterprise Value to Revenue 758.68
Enterprise Value to EBITDA -1.09
Shares Outstanding 187.31M
Shares Floating 186.87M
Shares Outstanding 187.31M
Shares Floating 186.87M
Percent Insiders 0.32
Percent Institutions 33.81

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.